Treatment of seasonal affective disorder: Unipolar versus bipolar differences

Sohn, Chang-Ho; Lam, Raymond W.

doi:10.1007/s11920-004-0014-z

Cited by 18 publications

(9 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For seasonal patterns, the first-line ADs in 2021 were the same as those recommended in 2017. These results were presumed to be a choice considering the (hypo)manic switching of seasonal patterns that can be related to bipolarity [ 24 ]; bupropion XR was approved for depressive patients with seasonal patterns in the US [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary

Seo

Bahk

Woo

et al. 2021

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective: In the 19 years since the Korean College of Neuropsychopharmacology and the Korean Society for Affective Disorders developed the Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) in 2002, four revisions have been conducted. Methods: To increase survey efficiency in this revision, to cover the general clinical practice, and to compare the results with previous KMAP-DD series, the overall structure of the questionnaire was maintained. The six sections of the questionnaire were as follows: 1) pharmacological treatment strategies for major depressive disorder (MDD) with/without psychotic features; 2) pharmacological treatment strategies for persistent depressive disorder and other depressive disorder subtypes; 3) consensus for treatment-resistant depression; 4) the choice of an antidepressant in the context of safety, adverse effects, and comorbid physical illnesses; 5) treatment strategies for special populations (children/adolescents, elderly, and women); and 6) non-pharmacological biological therapies. Recommended first-, second-, and third-line strategies were derived statistically. Results: There has been little change in the four years since KMAP-DD 2017 due to the lack of newly introduced drug or treatment strategies. However, shortened waiting time between the initial and subsequent treatments, increased preference for atypical antipsychotics (AAPs), especially aripiprazole, and combination strategies with AAPs yield an active and somewhat aggressive treatment trend in Korea. Conclusion: We expect KMAP-DD to provide clinicians with useful information about the specific strategies and medications appropriate for treating patients with MDD by bridging the gap between clinical real practice and the evidence-based world.

show abstract

Section: Discussionmentioning

confidence: 99%

Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary

Seo

Bahk

Woo

et al. 2021

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

show abstract

“…Selective serotonin reuptake inhibitors (SSRIs) have been utilized in large randomized controlled trials to treat seasonal depression, 4 but their effectiveness and safety for seasonal depressive symptoms in individuals with BP remain to be demonstrated. Vortioxetine is an antidepressant with effects equivalent to those of SSRIs (e.g., escitalopram).…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report

Yamaguchi,

Takagi,

Takahashi

et al. 2024

PCN Reports

View full text Add to dashboard Cite

BackgroundWe present a case report on the efficacy of the short‐term application of vortioxetine in managing winter depression in patients with seasonal bipolar disorder (BP). Standard treatment strategies for BP may not adequately address seasonal depressive symptoms during winter in patients with seasonal BP patterns. Depressive symptoms during winter may be linked to seasonal changes in serotonin transporter binding, such as a decrease in synaptic serotonin levels, necessitating alternative approaches. Although antidepressants, including vortioxetine, are effective in treating seasonal monopolar depression, their efficacy and safety in treating depression in patients with seasonal BP patterns remain unclear.Case PresentationThis case report focuses on a 44‐year‐old male patient diagnosed with seasonal BP who had recurrent depressive episodes, specifically during winter. Notably, the patient had a significant decrease in recurrent episodes after short‐term seasonal vortioxetine use without inducing mania or rapid cycling.ConclusionOur study highlights the potential effectiveness of a seasonal, short‐term treatment strategy with antidepressants, including vortioxetine, for winter depression in individuals with BP.

show abstract

“…In the last decade, however, research has shown that there is a remarkable resemblance between the pathophysiology of seasonal affective disorder and a bipolar disorder (Geoffroy et al 2014(Geoffroy et al , 2015. It has even been suggested that 11-50% of the patients with a seasonal depression actually can be diagnosed with a bipolar disorder (Sohn and Lam 2004). This, in combination with low response rates for antidepressants and their potential risk of inducing a (hypo)manic state, prompted clinical studies to investigate the effects and risks of light therapy for bipolar depression (Zhang et al 2013;Goldberg and Truman 2003;Tondo et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Treating winter depressive episodes in bipolar disorder: an open trial of light therapy

Hout¹,

Rops²,

Simons

2020

Int J Bipolar Disord

View full text Add to dashboard Cite

Background Light therapy has been used to treat winter depression in bipolar disorder, although the dose, duration, and timing of treatment have differed. The present study is an open trial of light therapy for depressive episodes in autumn/winter using a Dutch protocol specific for patients with a bipolar disorder. Methods Data were collected for the seasons September–April 2017–2018 and September–April 2018–2019. In total, 58 patients received light therapy for a minimum of 7 days and a maximum of 21 days; there was a follow-up measurement after two weeks. Outcomes were quick inventory of depressive symptomatology (QIDS) scores and side effects. Results QIDS scores were significantly lower at the last day of therapy (B = − 6.00, p < 0.001) and 2 weeks after the end of treatment (B = − 6.55, p < 0.001) compared with pre-intervention. Remission (QIDS ≤ 5) was reached in 55% of the treatments and response (50% symptom reduction) in 57% of the treatments. Side effects were mild; two hypomanic periods occurred. Conclusions The Dutch light therapy protocol for patients with a bipolar disorder may be effective in treating a seasonal depression and side effects are mild. Light therapy deserves a prominent place in the treatment because effects may be large and quick.

show abstract

Treatment of seasonal affective disorder: Unipolar versus bipolar differences

Cited by 18 publications

References 82 publications

Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary

Korean Medication Algorithm for Depressive Disorder 2021, Fourth Revision: An Executive Summary

Effectiveness of vortioxetine for winter depression in bipolar disorder: A case report

Treating winter depressive episodes in bipolar disorder: an open trial of light therapy

Contact Info

Product

Resources

About